Pharmacovigilance study of the association between progestogen and depression based on the FDA adverse event reporting System (FAERS)
Abstract Progestogens commonly used in the clinic include levonorgestrel, etonogestrel, medroxyprogesterone, hydroxyprogesterone, progesterone, desogestrel, and megestrol. Progestogens are widely used for contraception and the treatment of endometriosis, threatened abortion and other diseases. Howev...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-85826-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544636106014720 |
|---|---|
| author | Hui Gao Xiaohan Zhai Yan Hu Hang Wu |
| author_facet | Hui Gao Xiaohan Zhai Yan Hu Hang Wu |
| author_sort | Hui Gao |
| collection | DOAJ |
| description | Abstract Progestogens commonly used in the clinic include levonorgestrel, etonogestrel, medroxyprogesterone, hydroxyprogesterone, progesterone, desogestrel, and megestrol. Progestogens are widely used for contraception and the treatment of endometriosis, threatened abortion and other diseases. However, the correlation between progestogen use and depression is not clear. Therefore, this study used data from the FDA Adverse Event Reporting System (FAERS) database to assess the relationship between progestogen levels and depression. In this study, all data from the first quarter of 2004 to the third quarter of 2024 were extracted and imported into SAS 9.4 software for data cleaning and analysis. The reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN) and Multi-item Gamma Poisson Shrinker (MGPS) were used for Bayesian analysis and disproportionation analysis. Levonorgestrel, medroxyprogesterone, etonogestrel and desogestrel presented positive signals for depression, and medroxyprogesterone also presented positive signals for major depression. Although none of the progestogens presented positive signals for suicide or self-harm, medroxyprogesterone presented a positive signal for suicidal ideation. Conclusion Analysis of data from the FAERS database revealed that levonorgestrel, medroxyprogesterone, etonogestrel, and desogestrel were correlated with depression. These findings provide real-world evidence of the potential risk of progestogen-related depression. |
| format | Article |
| id | doaj-art-0019abf4ae274d0ebf330afaa80b7f6a |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-0019abf4ae274d0ebf330afaa80b7f6a2025-01-12T12:22:01ZengNature PortfolioScientific Reports2045-23222025-01-0115111010.1038/s41598-025-85826-1Pharmacovigilance study of the association between progestogen and depression based on the FDA adverse event reporting System (FAERS)Hui Gao0Xiaohan Zhai1Yan Hu2Hang Wu3Heze Medical CollegeDepartment of Pharmacy, The First Affiliated Hospital of Dalian Medical UniversityDepartment of Pharmacy, The Second Affiliated Hospital of Dalian Medical UniversityDepartment of pharmacy, Heze UniversityAbstract Progestogens commonly used in the clinic include levonorgestrel, etonogestrel, medroxyprogesterone, hydroxyprogesterone, progesterone, desogestrel, and megestrol. Progestogens are widely used for contraception and the treatment of endometriosis, threatened abortion and other diseases. However, the correlation between progestogen use and depression is not clear. Therefore, this study used data from the FDA Adverse Event Reporting System (FAERS) database to assess the relationship between progestogen levels and depression. In this study, all data from the first quarter of 2004 to the third quarter of 2024 were extracted and imported into SAS 9.4 software for data cleaning and analysis. The reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN) and Multi-item Gamma Poisson Shrinker (MGPS) were used for Bayesian analysis and disproportionation analysis. Levonorgestrel, medroxyprogesterone, etonogestrel and desogestrel presented positive signals for depression, and medroxyprogesterone also presented positive signals for major depression. Although none of the progestogens presented positive signals for suicide or self-harm, medroxyprogesterone presented a positive signal for suicidal ideation. Conclusion Analysis of data from the FAERS database revealed that levonorgestrel, medroxyprogesterone, etonogestrel, and desogestrel were correlated with depression. These findings provide real-world evidence of the potential risk of progestogen-related depression.https://doi.org/10.1038/s41598-025-85826-1DepressionProgestogenPharmacovigilanceAdverse event reporting systemEpidemiology |
| spellingShingle | Hui Gao Xiaohan Zhai Yan Hu Hang Wu Pharmacovigilance study of the association between progestogen and depression based on the FDA adverse event reporting System (FAERS) Scientific Reports Depression Progestogen Pharmacovigilance Adverse event reporting system Epidemiology |
| title | Pharmacovigilance study of the association between progestogen and depression based on the FDA adverse event reporting System (FAERS) |
| title_full | Pharmacovigilance study of the association between progestogen and depression based on the FDA adverse event reporting System (FAERS) |
| title_fullStr | Pharmacovigilance study of the association between progestogen and depression based on the FDA adverse event reporting System (FAERS) |
| title_full_unstemmed | Pharmacovigilance study of the association between progestogen and depression based on the FDA adverse event reporting System (FAERS) |
| title_short | Pharmacovigilance study of the association between progestogen and depression based on the FDA adverse event reporting System (FAERS) |
| title_sort | pharmacovigilance study of the association between progestogen and depression based on the fda adverse event reporting system faers |
| topic | Depression Progestogen Pharmacovigilance Adverse event reporting system Epidemiology |
| url | https://doi.org/10.1038/s41598-025-85826-1 |
| work_keys_str_mv | AT huigao pharmacovigilancestudyoftheassociationbetweenprogestogenanddepressionbasedonthefdaadverseeventreportingsystemfaers AT xiaohanzhai pharmacovigilancestudyoftheassociationbetweenprogestogenanddepressionbasedonthefdaadverseeventreportingsystemfaers AT yanhu pharmacovigilancestudyoftheassociationbetweenprogestogenanddepressionbasedonthefdaadverseeventreportingsystemfaers AT hangwu pharmacovigilancestudyoftheassociationbetweenprogestogenanddepressionbasedonthefdaadverseeventreportingsystemfaers |